Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection

This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Staphylococcus lugdunensis prosthetic joint infection of the hip. The patient has exhausted all conventional therapies, both surgical and medical, at considerable detriment to their quality of life. The treatment involves 2 intra-articular injections of bacteriophages into the joint and surrounding area and 14 days of intravenous phage therapy. The goal is to eliminate the infection and prevent further complications, providing a potential new treatment avenue for patients with difficult-to-treat infections.

NCT Number	NCT07461337
Lead Sponsor	University of Calgary Collaborators: Qeen Biotechnologies
Conditions	Prosthetic Joint Infections of Hip, Bacteriophage Therapy
Enrollment	1 participants
Start Date	2026-03
Primary Completion	2027-03 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2026-03-10